Cargando…
Relationship between Urinary N-Desmethyl-Acetamiprid and Typical Symptoms including Neurological Findings: A Prevalence Case-Control Study
Neonicotinoid insecticides are nicotinic acetylcholine receptor agonists used worldwide. Their environmental health effects including neurotoxicity are of concern. We previously determined a metabolite of acetamiprid, N-desmethyl-acetamiprid in the urine of a patient, who exhibited some typical symp...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633099/ https://www.ncbi.nlm.nih.gov/pubmed/26535579 http://dx.doi.org/10.1371/journal.pone.0142172 |
_version_ | 1782399148760236032 |
---|---|
author | Marfo, Jemima Tiwaa Fujioka, Kazutoshi Ikenaka, Yoshinori Nakayama, Shouta M. M. Mizukawa, Hazuki Aoyama, Yoshiko Ishizuka, Mayumi Taira, Kumiko |
author_facet | Marfo, Jemima Tiwaa Fujioka, Kazutoshi Ikenaka, Yoshinori Nakayama, Shouta M. M. Mizukawa, Hazuki Aoyama, Yoshiko Ishizuka, Mayumi Taira, Kumiko |
author_sort | Marfo, Jemima Tiwaa |
collection | PubMed |
description | Neonicotinoid insecticides are nicotinic acetylcholine receptor agonists used worldwide. Their environmental health effects including neurotoxicity are of concern. We previously determined a metabolite of acetamiprid, N-desmethyl-acetamiprid in the urine of a patient, who exhibited some typical symptoms including neurological findings. We sought to investigate the association between urinary N-desmethyl-acetamiprid and the symptoms by a prevalence case-control study. Spot urine samples were collected from 35 symptomatic patients of unknown origin and 50 non-symptomatic volunteers (non-symptomatic group, NSG, 4–87 year-old). Patients with recent memory loss, finger tremor, and more than five of six symptoms (headache, general fatigue, palpitation/chest pain, abdominal pain, muscle pain/weakness/spasm, and cough) were in the typical symptomatic group (TSG, n = 19, 5–69 year-old); the rest were in the atypical symptomatic group (ASG, n = 16, 5–78 year-old). N-desmethyl-acetamiprid and six neonicotinoids in the urine were quantified by liquid chromatography-tandem mass spectrometry. The detection of N-desmethyl-acetamiprid was the most frequent and highest in TSG (47.4%, 6.0 ppb (frequency, maximum)), followed by in ASG (12.5%, 4.4 ppb) and in NSG (6.0%, 2.2 ppb), however acetamiprid was not detected. Thiamethoxam was detected in TSG (31.6%, 1.4 ppb), in ASG (6.3%, 1.9 ppb), but not in NSG. Nitenpyram was detected in TSG (10.5%, 1.2 ppb), in ASG (6.3%, not quantified) and in NSG (2.0%, not quantified). Clothianidin was only detected in ASG (6.3%, not quantified), and in NSG (2.0%, 1.6 ppb). Thiacloprid was detected in ASG (6.3%, 0.1 ppb). The cases in TSG with detection of N-desmethyl-acetamiprid and thiamethoxam were aged 5 to 62 years and 13 to 62 years, respectively. Detection of N-desmethyl-acetamiprid was associated with increased prevalence of the symptoms (odds ratio: 14, 95% confidence interval: 3.5–57). Urinary N-desmethyl-acetamiprid can be used as a biomarker for environmental exposure to acetamiprid. Further multi-centered clinical research in larger patients groups with more metabolites analysis is needed. |
format | Online Article Text |
id | pubmed-4633099 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-46330992015-11-13 Relationship between Urinary N-Desmethyl-Acetamiprid and Typical Symptoms including Neurological Findings: A Prevalence Case-Control Study Marfo, Jemima Tiwaa Fujioka, Kazutoshi Ikenaka, Yoshinori Nakayama, Shouta M. M. Mizukawa, Hazuki Aoyama, Yoshiko Ishizuka, Mayumi Taira, Kumiko PLoS One Research Article Neonicotinoid insecticides are nicotinic acetylcholine receptor agonists used worldwide. Their environmental health effects including neurotoxicity are of concern. We previously determined a metabolite of acetamiprid, N-desmethyl-acetamiprid in the urine of a patient, who exhibited some typical symptoms including neurological findings. We sought to investigate the association between urinary N-desmethyl-acetamiprid and the symptoms by a prevalence case-control study. Spot urine samples were collected from 35 symptomatic patients of unknown origin and 50 non-symptomatic volunteers (non-symptomatic group, NSG, 4–87 year-old). Patients with recent memory loss, finger tremor, and more than five of six symptoms (headache, general fatigue, palpitation/chest pain, abdominal pain, muscle pain/weakness/spasm, and cough) were in the typical symptomatic group (TSG, n = 19, 5–69 year-old); the rest were in the atypical symptomatic group (ASG, n = 16, 5–78 year-old). N-desmethyl-acetamiprid and six neonicotinoids in the urine were quantified by liquid chromatography-tandem mass spectrometry. The detection of N-desmethyl-acetamiprid was the most frequent and highest in TSG (47.4%, 6.0 ppb (frequency, maximum)), followed by in ASG (12.5%, 4.4 ppb) and in NSG (6.0%, 2.2 ppb), however acetamiprid was not detected. Thiamethoxam was detected in TSG (31.6%, 1.4 ppb), in ASG (6.3%, 1.9 ppb), but not in NSG. Nitenpyram was detected in TSG (10.5%, 1.2 ppb), in ASG (6.3%, not quantified) and in NSG (2.0%, not quantified). Clothianidin was only detected in ASG (6.3%, not quantified), and in NSG (2.0%, 1.6 ppb). Thiacloprid was detected in ASG (6.3%, 0.1 ppb). The cases in TSG with detection of N-desmethyl-acetamiprid and thiamethoxam were aged 5 to 62 years and 13 to 62 years, respectively. Detection of N-desmethyl-acetamiprid was associated with increased prevalence of the symptoms (odds ratio: 14, 95% confidence interval: 3.5–57). Urinary N-desmethyl-acetamiprid can be used as a biomarker for environmental exposure to acetamiprid. Further multi-centered clinical research in larger patients groups with more metabolites analysis is needed. Public Library of Science 2015-11-04 /pmc/articles/PMC4633099/ /pubmed/26535579 http://dx.doi.org/10.1371/journal.pone.0142172 Text en © 2015 Marfo et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Marfo, Jemima Tiwaa Fujioka, Kazutoshi Ikenaka, Yoshinori Nakayama, Shouta M. M. Mizukawa, Hazuki Aoyama, Yoshiko Ishizuka, Mayumi Taira, Kumiko Relationship between Urinary N-Desmethyl-Acetamiprid and Typical Symptoms including Neurological Findings: A Prevalence Case-Control Study |
title | Relationship between Urinary N-Desmethyl-Acetamiprid and Typical Symptoms including Neurological Findings: A Prevalence Case-Control Study |
title_full | Relationship between Urinary N-Desmethyl-Acetamiprid and Typical Symptoms including Neurological Findings: A Prevalence Case-Control Study |
title_fullStr | Relationship between Urinary N-Desmethyl-Acetamiprid and Typical Symptoms including Neurological Findings: A Prevalence Case-Control Study |
title_full_unstemmed | Relationship between Urinary N-Desmethyl-Acetamiprid and Typical Symptoms including Neurological Findings: A Prevalence Case-Control Study |
title_short | Relationship between Urinary N-Desmethyl-Acetamiprid and Typical Symptoms including Neurological Findings: A Prevalence Case-Control Study |
title_sort | relationship between urinary n-desmethyl-acetamiprid and typical symptoms including neurological findings: a prevalence case-control study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633099/ https://www.ncbi.nlm.nih.gov/pubmed/26535579 http://dx.doi.org/10.1371/journal.pone.0142172 |
work_keys_str_mv | AT marfojemimatiwaa relationshipbetweenurinaryndesmethylacetamipridandtypicalsymptomsincludingneurologicalfindingsaprevalencecasecontrolstudy AT fujiokakazutoshi relationshipbetweenurinaryndesmethylacetamipridandtypicalsymptomsincludingneurologicalfindingsaprevalencecasecontrolstudy AT ikenakayoshinori relationshipbetweenurinaryndesmethylacetamipridandtypicalsymptomsincludingneurologicalfindingsaprevalencecasecontrolstudy AT nakayamashoutamm relationshipbetweenurinaryndesmethylacetamipridandtypicalsymptomsincludingneurologicalfindingsaprevalencecasecontrolstudy AT mizukawahazuki relationshipbetweenurinaryndesmethylacetamipridandtypicalsymptomsincludingneurologicalfindingsaprevalencecasecontrolstudy AT aoyamayoshiko relationshipbetweenurinaryndesmethylacetamipridandtypicalsymptomsincludingneurologicalfindingsaprevalencecasecontrolstudy AT ishizukamayumi relationshipbetweenurinaryndesmethylacetamipridandtypicalsymptomsincludingneurologicalfindingsaprevalencecasecontrolstudy AT tairakumiko relationshipbetweenurinaryndesmethylacetamipridandtypicalsymptomsincludingneurologicalfindingsaprevalencecasecontrolstudy |